Glipizide Needed to Meet Growing Numbers of Patients with Type 2 Diabetes

Glipizide Needed to Meet Growing Numbers of Patients with Type 2 Diabetes

Glipizide 29094-61-9Glipizide, CAS number 29094-61-9, is also known as Glucotrol XL, which is marketed by Pfizer. With the patent due to expire in January of 2014, glipizide is set up for success as a generic alternative treatment for patients with type 2 diabetes. As an oral blood-glucose-lowering drug of the sulfonylurea class, glipizide is offered in five and ten milligram tablets. Serious adverse reactions from patients who have taken glucotrol, or glipizide, have been rarely reported. Side effects include mild dizziness, drowsiness and minor headache. Generally well tolerated, LGM Pharma is a provider of the API glipizide, and offers complete and extensive support for researchers and developers.

Designed for patients who are non insulin dependent, glipizide is effective when used alongside diet and exercise. Glipizide works as it aids the pancreas in making more insulin, and also helping the cells respond better to insulin. This in turn helps to lower blood sugar and keep it under better control for patients with type 2 diabetes.

Facts from The National Diabetes Association reveal astounding statistics regarding the prevalence of type 2 diabetes. For example, type 2 diabetes is the most common form of diabetes, and it is more common in African Americans, Latinos, Native Americans, Asian Americans, Native Pacific Islanders, as well as the elderly population. Diabetic Retinopathy is the leading cause of blindness in patients with type 2 diabetes, ages 20-74. In addition to this grave news, type 2 diabetes is the leading cause of kidney failure, accounting for 44% of adult cases in 2008. These alarming statistics are quite telling, and act as a message to the medical community that there is a need for a greater availability of generic drugs to combat this disease.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service